Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FPV-CV301
- Development stage
- Unknown
- Lead developer
- Bavarian Nordic
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
FPV-CV301 is a recombinant fowlpox viral vector vaccine that serves as the boosting component in the CV301 cancer vaccine regimen. It contains transgenes encoding two tumor-associated antigens (CEA and MUC1) and three costimulatory molecules (TRICOM: B7.1, ICAM-1, and LFA-3). Used after priming with MVA-BN-CV301, it aims to generate and maintain immune responses against tumors that overexpress CEA and MUC1.
- Other names
- Fowlpox-CV301Fowlpox-CV-301Fowlpox-CV 301
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on FPV-CV301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FPV-CV301.